Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 4 | 2012 | 589 | 0.510 |
Why?
|
| Biomarkers, Tumor | 4 | 2014 | 1319 | 0.440 |
Why?
|
| Endonucleases | 2 | 2014 | 34 | 0.380 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2012 | 52 | 0.340 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2009 | 49 | 0.290 |
Why?
|
| Genes, p53 | 1 | 2009 | 67 | 0.280 |
Why?
|
| Receptors, Cell Surface | 1 | 2009 | 370 | 0.250 |
Why?
|
| Endometrial Hyperplasia | 1 | 2005 | 6 | 0.230 |
Why?
|
| Antigens, CD | 1 | 2009 | 552 | 0.230 |
Why?
|
| DNA-Binding Proteins | 2 | 2014 | 1484 | 0.220 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2005 | 49 | 0.220 |
Why?
|
| Progestins | 1 | 2005 | 65 | 0.220 |
Why?
|
| Endometrial Neoplasms | 1 | 2005 | 205 | 0.190 |
Why?
|
| Adenocarcinoma | 1 | 2009 | 923 | 0.170 |
Why?
|
| Carboplatin | 2 | 2012 | 161 | 0.170 |
Why?
|
| Paclitaxel | 2 | 2012 | 256 | 0.160 |
Why?
|
| Immunohistochemistry | 3 | 2014 | 1705 | 0.140 |
Why?
|
| Choline-Phosphate Cytidylyltransferase | 1 | 2014 | 3 | 0.110 |
Why?
|
| Disease-Free Survival | 2 | 2014 | 768 | 0.100 |
Why?
|
| Paraffin Embedding | 1 | 2012 | 31 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2012 | 1961 | 0.090 |
Why?
|
| DNA, Neoplasm | 1 | 2012 | 158 | 0.090 |
Why?
|
| Neoplasm Staging | 2 | 2012 | 1465 | 0.080 |
Why?
|
| Thiazoles | 1 | 2011 | 139 | 0.080 |
Why?
|
| Cisplatin | 1 | 2012 | 339 | 0.080 |
Why?
|
| Endoglin | 1 | 2009 | 19 | 0.070 |
Why?
|
| Thrombospondin 1 | 1 | 2009 | 28 | 0.070 |
Why?
|
| Serpins | 1 | 2009 | 28 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2014 | 643 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 1 | 2014 | 562 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 1268 | 0.070 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2009 | 93 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2009 | 74 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 1 | 2009 | 284 | 0.060 |
Why?
|
| Pyrimidines | 1 | 2011 | 519 | 0.060 |
Why?
|
| Genotype | 1 | 2012 | 1847 | 0.060 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 2117 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2009 | 550 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 1742 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2014 | 8284 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 1186 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 2137 | 0.050 |
Why?
|
| Aged | 4 | 2014 | 25955 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2008 | 1145 | 0.040 |
Why?
|
| Middle Aged | 4 | 2014 | 35971 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 2660 | 0.040 |
Why?
|
| Female | 6 | 2014 | 78304 | 0.040 |
Why?
|
| Disease Progression | 1 | 2005 | 2847 | 0.030 |
Why?
|
| Adult | 3 | 2012 | 40489 | 0.030 |
Why?
|
| Humans | 6 | 2014 | 144667 | 0.030 |
Why?
|
| Young Adult | 1 | 2012 | 14122 | 0.030 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2011 | 14 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2011 | 47 | 0.020 |
Why?
|
| Dasatinib | 1 | 2011 | 57 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2011 | 352 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1505 | 0.020 |
Why?
|
| ROC Curve | 1 | 2008 | 618 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 835 | 0.010 |
Why?
|
| Gene Expression | 1 | 2011 | 1476 | 0.010 |
Why?
|
| Prognosis | 1 | 2014 | 4312 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2014 | 5957 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2011 | 3523 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2014 | 7994 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2008 | 3603 | 0.010 |
Why?
|
| Male | 1 | 2014 | 72431 | 0.000 |
Why?
|